Starting on
SCEMBLIX
More people achieved a major molecular response (MMR) with SCEMBLIX than with the most commonly used TKIs*.
*Tyrosine kinase inhibitors (TKIs) are a class of targeted oral treatments used to treat Ph+ CML-CP.
SCEMBLIX vs the TKIs doctors use most
In a clinical study, nearly 7 out of 10 newly diagnosed patients achieved MMR with SCEMBLIX at 48 weeks, compared to nearly 5 out of 10 people who achieved MMR with imatinib, TASIGNA® (nilotinib), Sprycel® (dasatinib), or Bosulif® (bosutinib).†
†TASIGNA is a registered trademark of Novartis. Bosulif is a registered trademark of Pfizer Inc. Sprycel is a registered trademark of Bristol-Myers Squibb Company.
SCEMBLIX vs imatinib
In a clinical study, nearly 7 out of 10 newly diagnosed patients achieved MMR with SCEMBLIX at 48 weeks compared with 4 out of 10 people with imatinib.
In these clinical studies, the most common side effects reported (≥20%) with SCEMBLIX were pain in the muscles, bones, or joints.
What is MMR?
Achieving a major molecular response, or MMR, is one of the treatment milestones in Ph+ CML in chronic phase. Ask your doctor to explain this goal and find out if MMR may be within your reach once you start treatment with SCEMBLIX.
Fewer patients had to stop taking SCEMBLIX due to side effects
Less than half as many people taking SCEMBLIX (4.5%) had to stop treatment due to side effects at 48 weeks than those taking one of the TKIs that doctors use most (10.4%).
How SCEMBLIX works
SCEMBLIX works differently than all other currently approved TKIs for Ph+ CML in chronic phase. It is the first and only TKI that is thought to bind to a different site within the abnormal protein that causes Ph+ CML in chronic phase. Your doctor may call this site the myristoyl pocket.
Ask your doctor about SCEMBLIX
Before you start on treatment for Ph+ CML in chronic phase, ask your doctor about the potential benefits and risks of different medications.
